A vital region for human glycoprotein hormone trafficking revealed by an LHB mutation. by Potorac, Iulia et al.
AUTHOR COPY ONLY
DOI: 10.1530/JOE-16-0384
http://joe.endocrinology-journals.org © 2016 Society for Endocrinology
Printed in Great Britain




















A vital region for human glycoprotein 
hormone trafficking revealed by an 
LHB mutation
Iulia Potorac1,*, Adolfo Rivero-Müller2,3,4,*, Ashutosh Trehan2,*, Michał Kiełbus4,  
Krzysztof Jozwiak5, Francois Pralong6, Aicha Hafidi7, Albert Thiry8,  
Jean-Jacques Ménagé9, Ilpo Huhtaniemi2,10, Albert Beckers1 and Adrian F Daly1
1Department of Endocrinology, Centre Hospitalier Universitaire de Liège, Université de Liège,  
Domaine Universitaire du Sart-Tilman, Liège, Belgium
2Department of Physiology, Institute of Biomedicine, University of Turku, Turku, Finland
3Faculty of Natural Sciences and Technology, Åbo Akademi University, Turku, Finland
4Department of Biochemistry and Molecular Biology, Medical University of Lublin, Lublin, Poland
5Laboratory of Medicinal Chemistry and Neuroengineering, Medical University of Lublin, Lublin, Poland
6Service of Endocrinology, Diabetology and Metabolism, Department of Medicine, CHU Vaudois,  
Lausanne, Switzerland
7Department of Diabetology and Metabolic Diseases, Centre Hospitalier Universitaire Ibn Sina, Rabat, Morocco
8Department of Pathology, Centre Hospitalier Universitaire de Liège, Université de Liège,  
Domaine Universitaire du Sart-Tilman, Liège, Belgium
9Endocrinology Practice, Fontainebleau, France
10Department of Surgery and Cancer, Institute of Reproductive and Developmental Biology, Hammersmith Campus, 
Imperial College London, London, UK
*(I Potorac, A Rivero-Müller and A Trehan contributed equally to this work)
Abstract
Glycoprotein hormones are complex hormonally active macromolecules. Luteinizing 
hormone (LH) is essential for the postnatal development and maturation of the male 
gonad. Inactivating Luteinizing hormone beta (LHB) gene mutations are exceptionally 
rare and lead to hypogonadism that is particularly severe in males. We describe a family 
with selective LH deficiency and hypogonadism in two brothers. DNA sequencing of LHB 
was performed and the effects of genetic variants on hormone function and secretion 
were characterized by mutagenesis studies, confocal microscopy and functional assays.  
A 20-year-old male from a consanguineous family had pubertal delay, hypogonadism 
and undetectable LH. A homozygous c.118_120del (p.Lys40del) mutation was 
identified in the patient and his brother, who subsequently had the same phenotype. 
Treatment with hCG led to pubertal development, increased circulating testosterone 
and spermatogenesis. Experiments in HeLa cells revealed that the mutant LH is 
retained intracellularly and showed diffuse cytoplasmic distribution. The mutated LHB 
heterodimerizes with the common alpha-subunit and can activate its receptor. Deletion 
of flanking glutamic acid residues at positions 39 and 41 impair LH to a similar extent 
as deletion of Lys40. This region is functionally important across all heterodimeric 
glycoprotein hormones, because deletion of the corresponding residues in hCG, 
follicle-stimulating hormone and thyroid-stimulating hormone beta-subunits also led 
to intracellular hormone retention. This novel LHB mutation results in hypogonadism 
due to intracellular sequestration of the hormone and reveals a discrete region in the 
protein that is crucial for normal secretion of all human glycoprotein hormones.
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Introduction
Luteinizing hormone (LH) belongs to the heterodimeric 
glycoprotein hormone family whose other members 
are human chorionic gonadotropin (hCG), follicle-
stimulating hormone (FSH) and thyroid-stimulating 
hormone (TSH) (Cahoreau et  al. 2015). They share a 
common alpha-subunit (CGA) that is non-covalently 
bound to a hormone-specific beta-subunit. Inactivating 
germline mutations of beta-subunit genes have been 
described for all glycoprotein hormones apart from 
hCG, probably due to the importance of hCG for 
pregnancy success.
Inactivating mutations of the LH beta-subunit 
gene (LHB) are exceptionally rare and have been 
reported as homozygous mutations in consanguineous 
kindreds; a compound heterozygous LHB mutation was 
also identified (Weiss et  al. 1992, Valdes-Socin et  al. 
2004, Lofrano-Porto et  al. 2007, Achard et  al. 2009, 
Basciani et  al. 2012). Affected males have pubertal 
delay that is usually associated with arrested 
spermatogenesis and infertility. Females have a 
milder phenotype with pubertal development and 
spontaneous menarche that is followed by anovulatory 
oligomenorrhoea/secondary amenorrhoea. Males with 
LHB mutations respond to hCG treatment, that stimu-
lates the LH-hCG receptor (LHCGR) in Leydig cells, 
leading to increased testosterone production, sexual 
maturation and improved spermatogenesis (Valdes-Socin 
et al. 2004, Lofrano-Porto et al. 2007, Achard et al. 2009, 
Valdes-Socin et al. 2009).
Study of rare inactivating mutations of glycoprotein 
hormone beta-subunit genes has provided important 
insights into their structural–functional relationships, 
their heterodimerization with CGA and their 
receptor interactions. Here, we report a LHB mutation 
in two homozygous brothers that resulted in a 
deletion of a lysine at position 40 of the LHB peptide. 
Unlike other LHB mutations, the mutant LHB was 
synthesized, formed heterodimers and activated 
the LHCGR in vitro. The deletion of lysine 40 led to 
marked intracellular retention of LHB subunit. Similar 
experimental deletions in the beta-subunits of the 
other glycoprotein hormones (hCG, FSH and TSH) 
led to an identical pattern of intracellular retention, 
indicating an important role for this region in 




After obtaining informed consent, genetic and 
hormonal studies were undertaken in members of 
the kindred. Genomic DNA was extracted from blood 
leucocytes and a 1082 bp amplicon containing the 
complete LHB was sequenced. Primer sequences with 
3′ end mismatches in the 3′ primer (to differentiate 
LHB from the similar hCGB) are shown in the 
Supplementary Materials and methods (see section on 
supplementary data given at the end of this article). 
Thirty-one members of the kindred were screened 
specifically for the mutation found in the propositus 
and his pre-pubertal brother (Fig. 1C).
Construction of mutant cDNA expression vectors
We first generated the AmCyan-P2A-mCherry vector, 
where nAmCyan (containing a nuclear localization signal, 
NLS) and mCherry are separated by P2A (a 22 amino 
acid self-cleaving peptide) such that upon expression of 
this vector, nAmCyan goes to nucleus while mCherry is 
retained in the cytoplasm (Supplementary Fig.  1). The 
plasmid contains restriction sites to allow insertion of 
genes of interest to act as fusion proteins with mCherry 
(with nAmCyan as a reporter), or as splitting proteins 
from mCherry where nAmCyan is replaced with the 
gene of interest. The AmCyan-P2A-mCherry plasmid 
can be accessed via the Addgene repository (Addgene 
plasmid # 45350, Supplementary Fig. 2).
The LHB wild-type (WT)- and mutant (Lys40del)-
expressing plasmids were generated by cloning 500 
basepair gBlocks (IDT) into the AmCyan-P2A-mCherry 
as a fusion protein with mCherry via Gibson assembly 
(NEB). This allows the expression of the LHB gene to be 
monitored by nuclear-AmCyan, while the LHB-mCherry 
could be observed during biosynthesis, transport and 
secretion. The final vectors (AmCyan-P2A-WT-LHB-
mCherry and AmCyan-P2A-Lys40del-LHB-mCherry) 
were used for all in vitro studies. Similarly, gBlocks of WT 
FSH beta (FSHB), TSH beta (TSHB) and hCG beta (hCGB) 
were cloned as fusion proteins with mCherry. In order 
to determine if the signal peptide of LHB is affected by 
the downstream amino acids, we replaced the LHB signal 
peptide in the LHB-Lys40del mutant for that of prolactin 
(PRL). This was done by inserting a gBlock coding 
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PRL-LHB-Lys40del into the AmCyan-P2A-mCherry 
by Gibson assembly as described above. The plasmid 
carrying CGA under the ubiquitin C promoter has been 
described previously (Ahtiainen et al. 2010).
Mutagenesis
The AmCyan-P2A-WT-LHB-mCherry, WT-FSHB, 
WT-hCGB or WT-TSHB plasmids were used as templates 
for all further mutations. All mutants were generated by 
REPLACR technology and were sequence-verified (Trehan 
et  al. 2016). Primers for mutagenesis are presented in 
Supplementary Tables  1 and 2. The sequences of all 
cloned genes are presented in Supplementary Fig. 3, 
and their gene products in Supplementary Fig. 4.
Signal transduction studies
HEK293 cells stably expressing a luminescent cAMP 
sensor (Glosensor-22F, Promega) and either LH/chorionic 
gonadotropin receptor (LHCGR) or follicle-stimulating 
hormone receptor (FSHR) have been described previously 
(Trehan et al. 2014) and are referred to as GS-LHCGR or 
GS-FSHR cells, respectively. Similar cAMP sensor cells 
transiently expressing the thyroid-stimulating hormone 
receptor (TSHR; GS-TSHR cells) were developed. HEK293 
cells were transiently transfected with WT and mutant 
constructs of LHB, FSHB, TSHB and hCGB, either alone or 
co-transfected with CGA, and 36 h later the cell culture 
medium was replaced with fresh DMEM/F12 medium 
(with 5% charcoal-treated serum) for 8 h. The medium 
was then collected and stored at −20°C and either 
Figure 1
Clinical characterization. (A and B) External genitalia of the patient before and after treatment with hCG for 12 months is shown, with evident increase 
in penile length, testicular volume and pilosity. (C) Kindred diagram showing consanguinity; carriers and affected patients with the p.Lys40del mutation 
of LHB are indicated. (D) Testicular biopsy (haematoxylin and eosin staining, 100×) showing seminiferous tubules with globally thickened basement 
membrane (black arrow). Spermatogenesis is present but arrested at the round spermatid stage (white arrow) and few Leydig cells are seen in the 
interstitial space (open arrow).
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directly used for cell stimulation or first concentrated 
using a microconcentrator (Millipore 10 kDa cut-off). 
Activation of LHCGR, FSHR or TSHR was measured by 
cAMP production, as a luminescent read-out (relative 
light units; RLU) and is represented as area under curve. 
All experiments were independently repeated at least 
three times in triplicate.
Confocal microscopy
AmCyan and mCherry were excited with 458 nm 
and 543 nm laser lines, and emissions were collected 
at 470–579 nm and 578–696 nm, respectively. Confocal 
microscopes (Zeiss LSM780 and LSM 510 META) were 
used for the experiments in living cells. Imaris software 
was used to export images as three-dimensional (3D) 
volume renders of the Z-stacks. Contrast was increased 
uniformly on the whole image, for WT-LHB, FSHB and 
hCGB to better represent the secretion vesicles that are 
heavily secreting their respective hormone subunits 
out of the cells, thus retaining very small quantities of 
mCherry-tagged hormones inside the cells.
Measurement of LHB and LHB/CGA
LHB and LHB/CGA were measured using 
commercial ELISA kits: DELFIA hLH Spec that used 
an immobilized antibody against hLHB and a labelled 
secondary antibody against a different hLHB or 
DELFIA hLH SPEC immobilized primary antibody 
with a labelled secondary antibody of DELFIA 
hFSH, which detects the common CGA, respectively 
(PerkinElmer).
3D modelling
As no crystal structure for the target, LHB, is avalable, 
we used X-ray crystallography structure of homologous 
hCG (1HRP.pdb) as a template. The residues which are 
not evolutionary conserved between the target and the 
template were replaced. All modelling and visualization 
was done using YASARA 11.11.2. package.
Diffusion assay: fluorescence recovery  
after photobleaching
Each fluorescence recovery after photobleaching 
experiment started with an image acquisition of a 
cell’s cytoplasm using 561 nm laser (525/50 nm 
excitation and 595/50 nm emission filter blocks) 
followed by a single-point bleach (non-scanning) in 
the cytoplasm area at full power of 405 nm laser for 
the minimum time required to photobleach most of 
cytoplasmic fluorescence (1–5 s). Fluorescence recovery 
was measured by starting a time-lapse acquisition 
within 0.25 s after bleaching. Image size was 512 × 512 
pixels and 450 scans over 120 s were performed. Pinhole 
size was set to the optimal value (12.77 μm confocal 
aperture). Normalized fluorescence was calculated as 
the ratio of intensity of bleached region fluorescence to 
intensity of reference region fluorescence. The lowest 
value of fluorescence intensity was estimated as 0.
Statistical analysis
Statistical analyses were performed using GraphPad 
Prism 6 software using one-way ANOVA. Statistical 




A 20-year-old male of North-African descent was 
referred for investigation of pubertal delay. He presented 
Table 1 Response to subcutaneous pulsatile GnRH pump stimulation. Samples were drawn at 12 h intervals from the start of  
the study (T0) through to 72 h (T72). 
T0 T12 T24 T36 T48 T60 T72
LH (RR: 2–10 IU/L) 1.1 0.3 0.2 0.7 0.7 0.5 0.6
FSH (RR: 1–8 IU/L) 31.7 19.8 19.9 27.1 27.8 25.7 24.0
α-Subunit (RR: <0.80 IU/L) 3.70 2.2 1.7 2.5 3.89 3.40 3.69
SHBG (RR: 10–50 nmol/L) 16.8 15 16.3 17.1 17.8 16.9 17.9
Total testosterone (RR: 2.5–10 ng/mL) 0.77 0.46 0.62 0.80 1.13 0.9 1.43
Free testosterone (RR: 70–280 ng/L) 19.0 11.8 15.5 19.7 27.8 22.4 35.4
RR, reference range; SHBG, sex hormone binding globulin.
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with a hypogonadal phenotype: tall stature (190 cm), 
scant androgen-dependent pilosity, bilateral 
gynecomastia, micropenis and low testicular volume 
(~7 mL) (Fig. 1A). He reported low libido and infrequent 
erections. Laboratory tests confirmed hypogonadism 
(total testosterone 0.64 ng/mL, reference range 
(RR): 2.5–10; 2.2 nmol/L, RR: 8.7–37.4) with low LH 
(0.4 IU/L, RR: 2–10), high FSH (19.6 IU/L, RR: 1–8) and 
high free α-subunit (3.6 IU/L, RR males <0.8). Inhibin 
B was normal (233.4 ng/L, RR: 105–439). Pituitary 
MRI was normal and his karyotype was 46, XY. The 
patient was the second of five siblings (2F, 3M) from 
a consanguineous kindred (Fig.  1C). One sister was 
investigated for infertility but had normal hormonal 
and ultrasound investigations; his other adult siblings 
had offspring. At the time of presentation, the patient’s 
youngest brother was pre-pubertal.
A spermiogram revealed azoospermia with rare round 
spermatid-like cells, but no elongated spermatids. On 
testicular biopsy a small number of Leydig cells were 
seen, accompanied by relative Sertoli cell hyperplasia, 
and seminiferous tubules with a thickened basement 
membrane and arrested spermatogenesis (Fig.  1D). As 
the cause of hypogonadism was isolated LH deficiency, 
treatment with hCG (3000 IU twice weekly) was started. 
This led to normalization of testosterone and FSH levels; 
after 12  months of therapy the patient had developed 
normal male secondary sexual characteristics with 
increased testicular volume (18 mL) (Fig.  1B). A repeat 
spermiogram found a marked quantitative and qualitative 
Figure 2
Functional and visual characterization of the LHB-Lys40del as compared with WT-LHB. (A) Medium was collected from HEK293 cells transfected with 
various plasmid combinations and used to stimulate LHCGR using GS-LHCGR reporter cells. The luminescent read-out is proportional to cAMP 
production. CGA alone, LHB alone or medium from untransfected cells (medium alone) resulted in no activation of the LHCGR. WT-LHB + CGA produced 
the expected activation, while the LHB-Lys40del + CGA mutant showed a minimal, significantly reduced response (P value <0.0001). (B) Confocal images 
of HeLa cells expressing WT-LHB shows that it is present only in secretory vesicles, while the LHB-Lys40del mutant is diffusely present throughout the 
cytoplasm. (C) A diffusion test shows that while the WT-LHB does not diffuse within the cell (it is strictly compartmentalized) the Lys40del freely diffuses 
which suggest that it is not compartmentalized but rather in the cytosol. The latter chart is representative of at least three independent experiments 
where up to 10 single cells were analyzed.
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improvement (200,000/mL with good mobility and 
normal shape for 50% of spermatozoa). After 14 months of 
hCG therapy, treatment was discontinued for two months 
and a dynamic hormonal study was performed using 
prolonged subcutaneous pulsatile GnRH administration 
(gonadorelin-HRF (Tramedico); 20 µg every 90 min for 
72 h) via a pump (PANOMAT-Disetronic). Circulating levels 
of LH, FSH, total and free testosterone, free alpha-subunit 
as well as sex hormone binding globulin were assessed 
every 12 h (Table 1). While total testosterone levels rose 
from 0.77 µg/L at T0 to 1.43 µg/L at T72 h, both testosterone 
and LH remained below the lower limit of normal 
(Table 1).
Sequencing of the LHB gene revealed a deletion of 
three nucleotides, c.118_120del, leading to an in-frame 
deletion of lysine 40 of the mature peptide (p.Lys40del). 
The mutation was found in a homozygous state in the 
propositus, his pre-pubertal brother and in a heterozygous 
state in his parents, his two sisters, a maternal uncle and 
his two daughters (Fig. 1C). During long-term follow-up 
of the kindred, the younger homozygous brother also 
displayed delayed puberty in his mid-teens that was 
accompanied by the same hormonal picture as his 
brother (no testicular biopsy was performed). Given the 
good clinical response to hCG treatment in other males 
with LHB mutation-related hypogonadism, he was treated 
in a similar fashion to his brother and completed puberty 
with normal secondary sexual characteristics.
Signal transduction
As expected, neither CGA nor WT-LHB resulted in receptor 
activation when expressed alone in HEK293 cells. WT-LHB 
fused with mCherry formed heterodimers with CGA and 
these dimers activated the LHCGR (Fig. 2A). In contrast, 
co-expression of the LHB-Lys40del mutant with CGA 
was not able to activate LHCGR. Confocal microscopy 
demonstrated that WT-LHB was concentrated mainly 
within secretory vesicles, while the LHB-Lys40del mutant 
was present diffusely throughout the cell (Fig.  2B). We 
performed a diffusion test in which normally trafficked 
proteins diffuse poorly into a photo-bleached region, 
while non-trafficked proteins rapidly diffuse into the 
bleached region (Cardarelli et al. 2012). As hypothesized, 
the normally trafficked WT-LHB diffused poorly while the 
LHB-Lys40del mutant rapidly diffused to the bleached 
Figure 3
Heterodimerization of LHB with CGA and LHCGR 
activation. (A) Either WT-LHB + CGA or LHB-
Lys40del + CGA were transiently over-expressed 
and media was collected 48 h after transfection 
and concentrated. The concentrated fractions 
were used to stimulate cells expressing the LHCGR 
and a cAMP sensor. The generation of cAMP was 
recorded. While the WT-LHB + CGA resulted in a 
very marked response, the LHB-Lys40del + CGA 
resulted in a minor response, yet significantly 
larger than CGA alone, LHB alone or the control 
media; (B) concentration of LHB and LHB + CGA in 
the media of cells transfected with CGA and 
either WT-LHB or LHB-Lys40del; (C) ratio between 
secreted LHB and LHB + CGA heterodimers; (D) the 
concentration of the WT-LHB + CGA was diluted 
to that of the mutant (LHB-Lys40del + CGA) and 
then their potential to activate the LHCGR was 
measured as generation of cAMP, they both show 
identical responses demonstrating that 
heterodimerization to CGA and LHCGR activation 
are unaffected by the mutation. The statistical 
difference (P value <0.0001) for all the 
comparisons is highlighted as compared with 
LHB-Lys40del + CGA.
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region (Fig. 2C). As nuclear-AmCyan levels were similar in 
WT and Lys40del-expressing cells (Fig. 2B), this indicated 
that the expression level of the both WT-LHB and 
LHB-Lys40del mutant was normal.
We then over-expressed the WT-LHB or LHB-
Lys40del in the presence of CGA, collected the 
media after 48 h and concentrated it. Concentrated 
WT-LHB + CGA strongly stimulated the luminescent 
reporter GS-LHCGR cells but concentrated LHB-
Lys40del + CGA showed only a small response, although 
it was significantly higher than CGA or WT-LHB alone, 
or control medium (Fig.  3A). In the concentrated 
media, the concentration of LHB-Lys40del was 234-
fold less than WT-LHB (Fig. 3B); there was no difference 
in the ratios of beta-subunit to heterodimer between 
the WT and mutated LHB (Fig.  3C). After diluting 
the LHB-WT 234-fold to equalize the concentration 
with that of LHB-Lys40del, both activated GS-LHCGR 
cells identically (Fig.  3D). This indicates that the 
LHB-Lys40del mutant heterodimerizes with CGA to a 
similar extent as WT-LHB and that the heterodimer, 
once formed, is fully functional in activating its 
receptor. The decreased LH seen in the clinical setting, 
therefore, likely is due to intracellular retention of the 
mutated protein.
Using 3D modelling, the Lys40 deletion appears to 
alter the conformation of a loop, which suggests that 
this region may be important for proper folding of the 
beta-subunit or formation of the quaternary structure 
(Fig. 4A and B). To determine if the conserved glutamic 
acid residues immediately adjacent to Lys40 contribute 
to biosynthesis, we generated deletions of Glu39 or 
Glu41. LHB-Glu39del or LHB-Glu41del resulted in the 
same effect as LHB-Lys40del (Fig. 4C). Mutagenesis of 
Lys40 to alanine, arginine or asparagine led to fully 
functional proteins when co-expressed with CGA 
that activated LHCGR to a similar extent as WT-LHB 
(Fig.  4C). We also ruled out that the Lys40 deletion 
affected secretion of LH by impairing the LHB signal 
peptide. We replaced the LHB signal peptide with that 
of prolactin (PRL-Lys40del), as the PRL signal peptide 
potently locates mutant proteins to the cell membrane 
Figure 4
3D modelling and mutagenesis. The WT-LHB and 
LHB-Lys40del are represented in 
heterodimerization with CGA (green structure). 
The position of Lys40 is shown in the WT setting 
(A) and indicates a potential interaction with 
Asp97, influencing the loop shape. Absence of 
Lys40 results in conformational changes in the 
loop (B). Adjacent glutamic acids (39 and 41) are 
show in the WT (A) mutant LHB (B) settings. (C) 
Mutagenesis of Lys40 to alanine (Lys40Ala), 
arginine (Lys40Arg), or asparagine (Lys40Asn) and 
further heterodimerization with CGA and 
activation of the LHCGR shows that Lys40 can be 
replaced by those amino acids without affecting 
the function of the LHB. Deletions of the glutamic 
acids before (Glu39del) or after (Glu41del) the 
Lys40, however, result in the functional 
inactivation of the LHB. (D) A Lys40del mutant 
where the signal peptide was swapped for that of 
prolactin (PRL) also resulted in minimal activation 
of the LHCGR. The statistical difference (P value 
<0.0001) is highlighted among samples as 
compared with LHB-Lys40del + CGA.
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(Rivero-Müller et al. 2010). The intracellular localization 
of PRL-Lys40del was similar to the LHB-Lys40del (data 
not shown), and had a similar lack of secretion or 
LHCGR activation (Fig. 4D).
Given the impact of the Lys40 deletion on LH, we 
assessed whether analogous amino acids of the other 
heterodimeric glycoprotein hormone beta-subunits were 
similarly important for their secretion and function. 
Figure 5
Functional characterization of wild-type and mutant glycoprotein hormone beta subunits. (A) Aligned glycoprotein beta subunits. Signal peptides are 
highlighted in yellow while the Lys40 (K40) position in LH beta and corresponding positions in other beta subunits are highlighted in green. (B, C, D) 
Confocal images of HeLa cells expressing WT-hCGB, FSHB and TSHB as fusion proteins with mCherry shows their localization in secretion vesicles. 
However, the mutant subunits (hCGB-Lys40del, FSHB-Lys32del and TSHB-Arg33del) fused with mCherry, shows an even intracellular localization and 
markedly reduced localization in secretory vesicles. (E) The lack of localization of hCGB-Lys40del, FSHB-Lys32del and TSHB-Arg33del mutants in secretion 
vesicles is supported by their reduced ability to stimulate their respective receptors and thus decreased cAMP production as compared with WT-hCGB, 
WT-FSHB and WT-TSHB, respectively. A statistically significant difference (P value <0.0001) was found in cAMP production between WT + CGA and 
mutant + CGA for all glycoprotein hormone beta subunits (hCGB, FSHB and TSHB).
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We aligned the amino acid sequences of human CGB, 
FSHB, TSHB and LHB with Clustal OMEGA program 
and the respective positions were deleted to generate 
hCGB_K40del, FSHB_K32del and TSHB_R33del (Fig. 5A) 
(Li et  al. 2015). Across all human glycoprotein hor-
mones, both cellular localization and cAMP generation 
were impaired to a very similar extent to that seen with 
LHB-Lys40del. Compared with WT hormones, these 
mutant proteins did not localize correctly to secretory 
vesicles and showed diffuse intracellular distribution 
(Fig.  5B, C, D). Furthermore, the mutant forms of 
hCG, FSH and TSH also had greatly decreased secretion 
and consequently demonstrated reduced activation 
of their respective receptors as compared with WT 
hormones, similar to the situation demonstrated with 
LHB-Lys40del (Fig. 5E).
Discussion
We report the clinical and molecular characterization 
of two male patients with delayed puberty due to a 
homozygous inactivating mutation of the LHB gene in 
a consanguineous family. The mutation was a deletion 
of codon 40 of the LHB DNA sequence, which encodes 
lysine at position 20 of the mature protein (the signal 
peptide of LH is 20 amino acids). This deletion induces a 
conformational change in the LH beta-subunit that does 
not affect its coupling with CGA but prevents correct 
trafficking of the dimeric hormone molecule through 
the endoplasmic reticulum, leading to nearly absent 
secretion. The LHB-Lys40del mutant is secreted >230-
fold less than WT-LHB, leading to decreased circulating 
LH that caused hypogonadism in the affected patients. 
The mutated LHB is, however, capable of dimerizing with 
CGA and activating the LHCGR.
Male sexual differentiation, development and 
reproductive function are strictly related to androgen 
secretion and action. Secretion of androgens depends 
on the functionality of the hCG-LH-LHCGR axis. In 
humans, placental hCG binds to the LHCGR, stimulating 
foetal Leydig cells to secrete testosterone during foetal 
development, thus ensuring stabilization of the Wolffian 
ducts and their differentiation into the internal male 
genital tract (Themmen et  al. 2000). Following the 
conversion of testosterone to dihydrotestosterone the 
latter induces the development of the prostate and 
external genital organs. Hence, males with inactivating 
LHCGR mutations have more severe phenotype at 
birth (e.g. pseudohermaphroditism) than those with 
inactivating LHB mutations that are born normal 
(Latronico & Arnhold 2013). Postnatally, LH becomes 
the LHCGR agonist, exerting its effect on adult Leydig 
cells from puberty onwards. To date, only five other 
inactivating mutations of the LHB have been described 
(Weiss et  al. 1992, Valdes-Socin et  al. 2004, Lofrano-
Porto et al. 2007, Achard et al. 2009, Basciani et al. 2012). 
Their clinical presentation is similar with pubertal arrest 
in males (Axelrod et  al. 1979, Valdes-Socin et  al. 2004, 
Lofrano-Porto et al. 2007, Achard et al. 2009, Basciani et al. 
2012) and secondary amenorrhoea/oligomenorrhoea, 
anovulation and infertility in females despite normal 
secondary sexual characteristics (Lofrano-Porto et  al. 
2007, Achard et  al. 2009, Basciani et  al. 2012). Due to 
the more dramatic clinical presentation, LHB mutations 
were initially found only in males; the female cases 
described are sisters of male index patients. Treatment 
of the two patients described here with hCG-normalized 
testosterone secretion, thereby enabling the acquisition 
of secondary sexual characteristics and improvement in 
sperm production.
Previous instances of LH inactivation were due to 
homozygous mutations that prevented binding to LHCGR 
(Axelrod et al. 1979, Weiss et al. 1992) or the formation of 
heterodimers (Valdes-Socin et al. 2004), deleted important 
cysteine residues (H30-I32del) (Achard et al. 2009), caused 
abnormal splicing of the LH beta-subunit (Lofrano-Porto 
et al. 2007) or presented with a compound heterozygous 
mutation of the signal peptide (L9–L12del) in combination 
with a mutation at an intronic splice donor site on the 
other allele (Basciani et al. 2012).
The genetic mechanism impairing LH action in this 
family differs from the others described previously. We 
showed that the Lys40del did not impair the expression 
of LHB, prevent heterodimerization or alter the ratio 
of LHB monomer to dimer. Furthermore, the mutated 
dimer bound to and activated its receptor, LHCGR. Faulty 
trafficking of the mutated dimeric LH caused absent 
LH secretion; instead of targeted transport to secretory 
vesicles, the mutated LH diffused generally into the 
cytoplasm. Substituting Lys40 with either a hydrophilic 
(arginine), a hydrophobic (alanine) or a neutral residue 
(asparagine) did not impair LH function. Deleting either 
of the glutamic acids that flank Lys40 resulted in an 
identical effect on receptor stimulation to that seen with 
Lys40del. This indicates that amino acids in this region are 
crucial for correct intracellular trafficking of LH during its 
synthesis, and deletions result in intracellular retention, 
lack of LH secretion and the observed clinical phenotype. 
The 3D model indicates that Lys40 is situated in a loop 
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between alpha helices and alterations in this loop appear 
to trigger a change in the peptide 3D structure.
Although the glycoprotein hormone family 
regulates diverse biological functions, the individual 
hormones share a significant structural similarity (Li 
& Ford 1998). The CGA and beta-subunits belong to 
the cystine-knot superfamily and have a similar tertiary 
structure with three elongated loops (Cahoreau et  al. 
2015). The C-terminal segment of the beta-subunit 
stabilizes the heterodimer by wrapping around the 
alpha-subunit like a seat belt and latching through a 
disulphide bond with a cysteine residue from loop 1 
of the beta-subunit (Lapthorn et  al. 1994, Xing et  al. 
2001, 2004). Lys40 is situated in the beta-1 loop, close 
to a cysteine residue that is part of the seat belt latch. 
However, deletion of Lys40 or its flanking glutamic 
acid residues appears not to impair the assembly 
of functional dimeric LH. Intriguingly, analogous 
mutations of hCG, FSH and TSH beta-subunits had 
a very similar effect to that seen in LH, with marked 
intracellular retention, minimal secretion and decreased 
receptor stimulation. This general effect of deletions 
in this discrete region across the glycoprotein beta-
subunits suggests impairment of a common step that 
precedes trafficking of hormones to secretory vesicles. 
This is most likely due to protein misfolding after the 
protein is undocked from the endoplasmic reticulum and 
before it enters the Golgi apparatus. The cytosolic diffusion 
of mutated protein seen on confocal microscopy for all 
the glycoprotein hormones suggests that misfolded 
protein has been re-exported out of the endoplasmic 
reticulum. While we would speculate that the misfolded 
glycoprotein hormone would undergo ubiquitination 
and proteasomal destruction, their continued presence 
throughout the cytoplasm argues against rapid 
degradation (Smith et al. 2011).
In conclusion, the clinical phenotype of 
hypogonadism in two brothers with a homozygous LHB 
mutation causing a single amino acid deletion reveals an 
important region for normal secretion of all four human 
glycoprotein hormones. These discrete changes led to 
intracellular retention of functional dimeric hormones 
that can have important clinical consequences. 
Additionally, we have developed a new system to test 
mutations in glycoprotein hormones that allows for easy 
visualization of expression and localization.
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